Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction

Abstract

Abciximab had important effects beyond the maintenance of large-vessel patency. It improved the recovery of microvascular perfusion and concomitantly enhanced the recovery of contractile function in the area at risk.

Editorial on “Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy” by Marcucci et al.

“…However, from the backgroundofthe presenteddataitseemslikelythat in addition to successful and complete reopening of the infarct-related coronaryartery, the degree of residualplateletactivation determinesthe extent of myocardialnecrosis despite combined antiplatelettherapy. The pres-©2007 Schattauer GmbH,Stuttgart ent study is also in agreement with previous findings that GPIIbIIIa inhibitors improve microcirculatory blood floww ithin the area at risk of the infarcted myocardium (11).…”

Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

“…28 Another potential mechanism of high local concentrations might be related to the antiinflammatory properties of abciximab. 7 These clinical considerations are supported by experimental data showing a dose-dependent platelet disaggregation. Concentrations that produced complete platelet disaggregation also induced partial displacement of platelet-bound fibrinogen, which might play a role in the clinical setting.…”

Relationship Between Myocardial Damage and C-Reactive Protein Levels Immediately After Onset of Acute Myocardial Infarction

“…Because AMI with elevated CRP levels immediately after the onset may have less myocardial damage and a more fragile culprit lesion, 7 it may be best managed by early implementation of a reliable reperfusion strategy, such as stent replacement or treatment with abciximab. 23,24 …”